Microvast Holdings announces departure of chief financial officer
On Tuesday, Piper Sandler adjusted its outlook on Vicarious Surgical Inc. (NYSE:RBOT), reducing the price target to $8.50 from the previous $10.50 while maintaining a Neutral rating on the stock. The new target sits below the stock’s current trading price of $9.19. According to InvestingPro data, analyst consensus remains cautiously optimistic with targets ranging from $8.50 to $13.00. This change follows the company’s announcement of its fourth-quarter results and future financial guidance.
Vicarious Surgical reported a fourth-quarter adjusted EPS of -$2.43, surpassing the expected -$2.69 by analysts. The company also provided its financial outlook for the year 2025, projecting an approximate full-year cash burn of $50 million. InvestingPro analysis reveals the company maintains a healthy current ratio of 7.44, with cash holdings exceeding debt levels. However, InvestingPro identifies several additional financial health indicators available to subscribers.
A significant development for Vicarious Surgical was the successful completion of the V1.0 system integration during the fourth quarter of 2024. This accomplishment is seen as a positive step towards the company’s goals. However, some minor supply chain issues were reported, affecting the timeline for first-in-human cases, which are now expected in late 2025, a slight delay from the previously anticipated mid-to-late 2025 schedule.
The company has since addressed these supply chain challenges. Piper Sandler’s analyst expressed continued enthusiasm for Vicarious Surgical’s unique technology. Nevertheless, the firm’s stance remains Neutral until further progress and clearer visibility towards the company’s commercialization are observed.
The updated price target of $8.50 reflects the analyst’s adjusted expectations following the recent developments and announcements made by Vicarious Surgical.
In other recent news, Vicarious Surgical Inc. announced its financial results for the fourth quarter of 2024, reporting an adjusted loss per share of $(2.43), which was better than both BTIG and consensus estimates. The company recorded zero revenue for the quarter, with total operating expenses amounting to $15.0 million. As of the end of 2024, Vicarious Surgical had a cash balance of approximately $49.1 million and expects a cash burn of about $50 million in 2025. The company has faced delays in its development milestones due to supply chain issues, impacting the timeline for clinical trials and regulatory submissions.
BTIG analysts have maintained a Neutral rating on Vicarious Surgical stock following these results. The company has made significant progress in operational efficiency, reducing total operating expenses by 17% year-over-year. Vicarious Surgical successfully integrated its Version 1.0 surgical robotic system, which features advanced capabilities such as a single 18mm incision. Looking ahead, Vicarious Surgical plans to submit its technical dossier by mid-2025 and aims to begin treating its first clinical patients by late 2025. The company has also expanded its partnerships with major academic health networks, including LSU Health New Orleans, Temple Health, and UI Health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.